Published online before print March 18, 2004, doi: 10.1161/01.STR.0000125012.36134.89
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:1041.)
© 2004 American Heart Association, Inc.
Original Contributions |
Trial Application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to Assist Priority Setting in Stroke
From National Stroke Research Institute (M.L.M., A.G.T., B.R.C., G.A.D., H.M.D.), Austin Health, Heidelberg Heights, Australia; Program Evaluation Unit (M.L.M., R.C., C.M.), University of Melbourne, Australia; Neurology Department (B.R.C., G.A.D., H.M.D.), Austin Health, Heidelberg Heights, Australia; and Department of Medicine (B.R.C., G.A.D., H.M.D.), University of Melbourne, Australia.
Correspondence to Marjory L. Moodie, Department of Public Health, School of Population Health, Program Evaluation Unit, 4/207 Bouverie Street, University of Melbourne, Victoria 3010, Australia. E-mail mmoodie{at}unimelb.edu.au
Background and Purpose— Cost-effectiveness data for stroke interventions are limited, and comparisons between studies are confounded by methodological inconsistencies. The aim of this study was to trial the use of the intervention module of the economic model, a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to facilitate evaluation and ranking of the options.
Methods— The approach involves using an economic model together with added secondary considerations. A consistent approach was taken using standard economic evaluation methods. Data from the North East Melbourne Stroke Incidence Study (NEMESIS) were used to model "current practice" (base case), against which 2 interventions were compared. A 2-stage process was used to measure benefit: health gains (expressed in disability-adjusted life years [DALYs]) and filter analysis. Incremental cost-effectiveness ratios (ICERs) were calculated, and probabilistic uncertainty analysis was undertaken.
Results— Aspirin, a low-cost intervention applicable to a large number of stroke patients (9153 first-ever cases), resulted in modest health benefits (946 DALYs saved) and a mean ICER (based on incidence costs) of US $1421 per DALY saved. Although the health gains from recombinant tissue-type plasminogen activator (rtPA) were less (155 DALYs saved), these results were impressive given the small number of persons (256) eligible for treatment. rtPA dominates current practice because it is more effective and cost-saving.
Conclusions— If used to assess interventions across the stroke care continuum, MORUCOS offers enormous capacity to support decision-making in the prioritising of stroke services.
Key Words: cerebrovascular disorders • cost-benefit analysis • aspirin • thrombolytic therapy
This article has been cited by other articles:
 |
|
 |
|
  B. Norrving, P. Wester, K. S. Sunnerhagen, A. Terent, A. Sohlberg, F. Berggren, P.-O. Wester, K. Asplund, for the Stroke Guidelines Working Group,, and National Board of Health and Welfare, Stockholm, S Beyond Conventional Stroke Guidelines: Setting Priorities Stroke, July 1, 2007; 38(7): 2185 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ehlers, G. Andersen, L. B. Clausen, M. Bech, and M. Kjolby Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke Stroke, January 1, 2007; 38(1): 85 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Demaerschalk and T. R. Yip Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States Stroke, November 1, 2005; 36(11): 2500 - 2503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Matchar and A. G. Rudd Health Policy and Outcomes Research 2004 Stroke, February 1, 2005; 36(2): 225 - 227. [Full Text] [PDF]
|
|